Mr. Malik is the President of Viatris. Mr. Malik joined the Viatris board of directors in 2020 after nine years of service on the Mylan board.
Mr. Malik is president of Viatris, a position he has held since November of 2020. Previously, he spent 14 years at Mylan. Throughout his time at Mylan, Mr. Malik held various senior roles, including executive vice president and chief operating officer from July 2009 to December 2012, head of Global Technical Operations from January 2007 to July 2009 and most recently as president. Mr. Malik joined Mylan in January 2007, when Mylan acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), where Malik served as chief executive officer from July 2005 to June 2008. Prior to joining Matrix, he served as head of Global Development and Registrations for Sandoz GmbH and head of Global Regulatory Affairs and head of Pharma Research for Ranbaxy. Mr. Malik announced his intention to retire as President of Viatris effective April 1, 2024, but will continue to serve as a member of the Board of directors following his retirement.
Key Skills and Experience:
Mr. Malik’s qualifications to serve on the Board include, among others, his experience regarding public company management, finance, accounting and capital market, global business, the healthcare industry, legal and regulatory oversight, risk oversight and compliance, and strategy and M&A acquired over his extensive career in the healthcare industry, including at Mylan where he was responsible for leading global commercial, scientific, operational, information technology and business and the development activities in more than 165 countries and territories and a portfolio of more than 7,500 products, a pipeline of approximately 1,200 products and more than 40 manufacturing facilities around the world. He also was integral in helping to develop the strategies for the company’s acquisitions over more than the last 10 years, as well as in the execution and integration of the acquisitions, and did this while ensuring a core commitment to improving patient access to medicines around the world. His skills and expertise have been further enhanced in his current role, where he is responsible for the day-to-day operations of the Company, overseeing the Company’s commercial business units, the Commercial Development, Medical, Information Technology and Quality functions, as well as R&D and Operations and where he has played a leading role in integrating Mylan and Upjohn, formerly a division of Pfizer, while stabilizing the business.
Current Private Company Boards:
- Biocon Biologics Limited
Former Public Company Boards:
- Mylan N.V.